SRC and lung cancer: Consistent with our findings, mutation and subsequent loss of the tumour suppressor function of NF1 has been reported in lung cancer cells which have acquired resistance to the SRC inhibitor dasatinib, and this was associated with active RAS-MAPK signalling [21].